FindTrial
Sign In

Efficacy and safety of tocilizumab mono-therapy in patients with adult-onset Still's disease

Efficacy and safety of tocilizumab mono-therapy in patients with adult-onset Still's disease - Treatment of AOSD by tocilizumab mono-therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000007019
Enrollment
40
Registered
2012-02-01
Start date
2012-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

tocilizumab monotherapy

Sponsors

Department of Rheumatology & Clinical Immunology,Saitama Medical Center, Saitama Medical Universitity
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: AOSD patients who fulfilled the AOSD classification criteria by Yamaguchi in 1992

Exclusion criteria

Exclusion criteria: 1) patients who are prohibited to use tocilizumab by the JCR guideline for proper tocilizumab use 2) patients who are thought to be inappropriate for the treatment with tocilizumab by their attending doctor

Design outcomes

Secondary

MeasureTime frame
Improvement of major clinical signs,treatment survival rate,patient's global assessment(by VAS),relapse rate and adverse events at week 52 and 104—

Primary

MeasureTime frame
Improvement of major clinical signs and symptoms at week 12 and 28 (fever, arthritis,skin eruption, leukocytosis, serum ferritin)—

Countries

Japan

Contacts

Public ContactRyota Sakai

Saitama Medical Center, Saitama Medical Universitity Department of Rheumatology & Clinical Immunology

r_sakai@saitama-med.ac.jp0492283574

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026